FIRST-Testosterone Side Effects
Generic name: testosterone
Medically reviewed by Drugs.com. Last updated on Feb 8, 2025.
Note: This document provides detailed information about FIRST-Testosterone Side Effects associated with testosterone. Some dosage forms listed on this page may not apply specifically to the brand name FIRST-Testosterone.
Applies to testosterone: nasal gel/jelly.
Other dosage forms:
Serious side effects of FIRST-Testosterone
Along with its needed effects, testosterone (the active ingredient contained in FIRST-Testosterone) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking testosterone:
More common side effects
- discomfort in the nose
- fever
- headache
- muscle aches
- sore throat
- stuffy or runny nose
- unusual tiredness or weakness
Less common side effects
- bloody nose
- body aches or pain
- chills
- cough
- difficulty with breathing
- ear congestion
- loss of voice
- pain or tenderness around the eyes and cheekbones
- sneezing
- tightness of the chest
Incidence not known
- anxiety
- chest pain
- dizziness or lightheadedness
- fainting
- fast heartbeat
- pain, redness, or swelling in the arm or leg
- sudden shortness of breath or troubled breathing
Other side effects of FIRST-Testosterone
Some side effects of testosterone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
- change in sense of smell
Precautions
It is very important that your doctor check your progress while you are using this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to use it. Blood and urine tests may be needed to check for unwanted effects.
Do not use Natesto® together with other medicines given into your nose (eg, oxymetazoline), unless your doctor says it is okay.
This medicine should not be used by women. Testosterone may cause birth defects if a pregnant woman comes in contact with the medicine. Make sure your doctor knows if your sexual partner is pregnant. If a pregnancy occurs while you are using this medicine, tell your doctor right away.
This medicine may cause nasal problems. Check with your doctor right away if you have a runny nose, congestion, sneezing, nosebleeds, nasal discomfort, nasal scabbing, or nasal dryness while using this medicine.
This medicine may cause blood clotting problems. Check with your doctor right away if you have a chest pain, trouble breathing, coughing up blood, numbness or weakness in your arm or leg, or on one side of your body, or pain in your lower leg (calf) while using this medicine.
This medicine may increase your risk of having a heart attack or stroke. Tell your doctor right away if you have chest pain that may spread to your arms, jaw, back, or neck, faintness, headache, nausea, vomiting, trouble breathing, trouble seeing or speaking, or unusual sweating.
This medicine may be habit-forming. If you feel that the medicine is not working as well, do not use more than your prescribed dose. Call your doctor for instructions.
Tell your doctor if your female partner or child starts to have male-like body changes while you are using this medicine. Such changes may include hair growth on the face, a deeper voice, or a significant increase in acne. The changes may also include an enlarged penis or clitoris, early development of pubic hair, increased erections or sexual desire, aggressive behavior, and bone problems.
In some cases, this medicine may decrease the amount of sperm men make and affect their ability to have children. If you plan to have children, talk with your doctor before using this medicine.
Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin. These could be symptoms of a serious liver problem.
This medicine may cause fluid retention (edema) in some patients. Tell your doctor right away if you have bloating or swelling of the face, arms, hands, lower legs, or feet, tingling of the hands or feet, or unusual weight gain or loss.
This medicine may affect the results of the prostate specific antigen (PSA) test, which may be used to detect prostate cancer. Make sure you tell all of your doctors that you are using this medicine.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
For healthcare professionals
Applies to testosterone: buccal film extended release, compounding powder, intramuscular solution, nasal gel, oral capsule, subcutaneous implant, subcutaneous solution, transdermal cream, transdermal film, transdermal film extended release, transdermal gel, transdermal ointment, transdermal solution.
General adverse events
The most frequently reported side effects with this drug are edema, acne, site pain, injection site erythema, cough or dyspnea during or immediately after injection.
The most frequently reported side effects with testosterone (the active ingredient contained in FIRST-Testosterone) topical are skin reaction (16.1%) and allergic contact dermatitis (up to 37%).[Ref]
Dermatologic
- Very common (10% or more): Testosterone topical: Skin reaction (16.1%), burn-like blisters (12%), itching, allergic contact dermatitis (up to 37%)
- Common (1% to 10%): Acne, induration, burning
- Uncommon (0.1% to 1%): Alopecia, erythema, rash (including rash popular), pruritus, dry skin, folliculitis (testosterone (the active ingredient contained in FIRST-Testosterone) topical)
- Frequency not reported: Seborrhea, urticaria, male pattern baldness, hirsutism injection site inflammation
- Postmarketing reports: Angioedema, angioneurotic edema, hyperhidrosis, discolored hair, leukocytoclastic vasculitis[Ref]
Endocrine
- Very common (10% or more): Accelerated growth
- Common (1% to 10%): Increased estradiol, hypogonadism
- Uncommon (0.1% to 1%): Increased blood testosterone (the active ingredient contained in FIRST-Testosterone) Frequency not reported: Signs of virilization in women (e.g., hoarseness, acne, hirsutism, menstrual irregularity, clitoral enlargement, and alopecia), precocious puberty (in prepubertal males)
- Postmarketing reports: Hyperparathyroidism, prolactin increased, testosterone increased[Ref]
Gastrointestinal
- Very common (10% or more): Testosterone buccal film: Gingivitis (32.6%)
- Common (1% to 10%): Diarrhea, oily stools (due to IM injection oily solvent); Testosterone topical: Gastroesophageal reflux disease, gastrointestinal bleeding, gum or mouth irritation (9.2%), taste bitter, gum pain, gum tenderness, gum edema, taste perversion
- Uncommon (0.1% to 1%): Nausea
- Rare (less than 0.1%): Abdominal pain
- Frequency not reported: Abdominal disorder, intraabdominal hemorrhage
- Postmarketing reports: Vomiting; Testosterone buccal film: Dry mouth, gingival swelling, lip swelling, mouth ulceration, stomatitis[Ref]
The majority of gum-related adverse events were transient.[Ref]
Local
- Very common (10% or more): Testosterone topical: Application site pruritus (up to 37%), application site blistering (12%)
- Common (1% to 10%): Injection site pain, injection site discomfort, injection site pruritus, erythema, injection site hematoma, injection site irritation, injection site inflammation; injection site reaction; Topical testosterone (the active ingredient contained in FIRST-Testosterone) Application site erythema, application site warmth, application site irritation, application site vesicles, application site exfoliation, application site burning, application site induration, bullae at application site, mechanical irritation at application site, rash at application site, contamination of application site
- Postmarketing reports: Injection site abscess, procedural pain, application site swelling (topical testosterone)[Ref]
Cardiovascular
- Common (1% to 10%): Hot flush, hypertension
- Uncommon (0.1% to 1%): Cardiovascular disorder
- Frequency not reported: Venous thromboembolism
- Postmarketing reports: Angina pectoris, cardiac arrest, cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, tachycardia, cerebral infarction, cerebrovascular accident, circulatory collapse, deep venous thrombosis, syncope, thromboembolism, thrombosis, venous insufficiency, stroke[Ref]
Genitourinary
- Common (1% to 10%): Abnormal prostate examination, benign prostate hyperplasia (BPH), ejaculation disorder, prostatitis
- Uncommon (0.1% to 1%): Prostate induration, prostatic disorder, testicular pain, decreased urine flow, urinary retention, urinary tract disorder, nocturia, dysuria
- Rare (less than 0.1%): Micturition disorders, epididymitis, bladder irritability, impotence, inhibition of testicular function and testicular atrophy
- Frequency not reported: Oligospermia, priapism, benign prostatic hyperplasia (prostatic growth to eugonadal state), excessive frequency and duration of erections; Pediatrics: Precocious sexual development, an increased frequency of erections, phallic enlargement
- Postmarketing reports: Prostate infection, calculus urinary, dysuria, hematuria, urinary tract disorder, pollakiuria, azoospermia[Ref]
Hematologic
- Common (1% to 10%): Polycythemia, hematocrit increased
- Uncommon (0.1% to 1%): Increased red blood cell count, increased hemoglobin, prolonged activated partial thromboplastin time, prolonged prothrombin time
- Frequency not reported: Blood and lymphatic system disorders, suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy
- Postmarketing reports: Thrombocytopenia, anemia[Ref]
Metabolic
- Common (1% to 10%): Weight increased, appetite increased, fluid retention (sodium, chloride, water, potassium, calcium, and inorganic phosphates)
- Uncommon (0.1% to 1%): Increased glycosylated hemoglobin, hypercholesterolemia, increased triglyceride
- Frequency not reported: Abnormal lipids (decrease in serum LDL, HDL, and triglycerides), metabolism and nutrition disorders, hypercalcemia
- Postmarketing reports: Hypoglycemia, diabetes mellitus, fluid retention, hyperlipidemia, hypertriglyceridemia, blood glucose increased[Ref]
Musculoskeletal
- Common (1% to 10%): Back pain, hemarthrosis (testosterone (the active ingredient contained in FIRST-Testosterone) topical)
- Uncommon (0.1% to 1%): Arthralgia, pain in extremity, muscle spasm, muscle strain, myalgia, musculoskeletal stiffness, increased creatine phosphokinase
- Frequency not reported: Pediatrics: Premature epiphyseal closure, increased bone formation
- Postmarketing reports: Musculoskeletal chest pain, musculoskeletal pain, myalgia, osteopenia, osteoporosis, systemic lupus erythematosus[Ref]
Nervous system
- Common (1% to 10%): Headache, vertigo (topical testosterone (the active ingredient contained in FIRST-Testosterone)
- Uncommon (0.1% to 1%): Migraine, tremor, dizziness
- Frequency not reported: Nervousness, paresthesia
- Postmarketing reports: Cerebrovascular insufficiency, reversible ischemic neurological deficiency, transient ischemic attack, amnesia[Ref]
Oncologic
- Common (1% to 10%): Prostatic specific antigen (PSA) increased, prostate cancer
- Uncommon (0.1% to 1%): Prostatic intraepithelial neoplasia
- Rare (less than 0.1%): Neoplasms benign, malignant, and unspecified (including cysts and polyps)[Ref]
Other
- Common (1% to 10%): Fatigue, hyperhidrosis; chills, body pain, smell disorder
- Uncommon (0.1% to 1%): Breast induration, breast pain, sensitive nipples, gynecomastia, increased estradiol, increased testosterone (the active ingredient contained in FIRST-Testosterone) asthenia, night sweats
- Rare (less than 0.1%): Fever, malaise
- Frequency not reported: Edema
- Postmarketing reports: Sudden hearing loss, tinnitus, Influenza like illness[Ref]
Psychiatric
- Common (1% to 10%): Irritability, insomnia, mood swings, aggression,
- Uncommon (0.1% to 1%): Depression, emotional disorder, restlessness, increased libido, decreased libido
- Frequency not reported: Hostility, anxiety
- Postmarketing reports: Korsakoff's psychosis nonalcoholic, male orgasmic disorder, restlessness, sleep disorder[Ref]
Respiratory
- Common (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitis
- Uncommon (0.1% to 1%): Cough, dyspnea, snoring, dysphonia
- Rare (less than 0.1%): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions
- Frequency not reported: Sleep apnea
- Postmarketing reports: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome[Ref]
Signs and symptoms of pulmonary microemboli may occur during or immediately after the injections and are reversible.[Ref]
Hepatic
- Uncommon (0.1% to 1%): Abnormal LFT, increased AST
- Rare (less than 0.1%): Abnormal hepatic function
- Frequency not reported: Jaundice, benign liver tumor, malignant liver tumor, liver enlargement, peliosis hepatitis
- Postmarketing reports: ALT increased, AST increased, bilirubin increased, transaminases increased, gamma-glutamyltransferase increased[Ref]
Hypersensitivity
- Uncommon (0.1% to 1%): Hypersensitivity reactions
- Frequency not reported: Anaphylactic reactions
- Postmarketing reports: Anaphylactic shock[Ref]
Ocular
- Uncommon (0.1% to 1%): Testosterone (the active ingredient contained in FIRST-Testosterone) topical: Lacrimation increased
- Postmarketing reports: Testosterone topical: Intraocular pressure increased, vitreous detachment[Ref]
Renal
- Postmarketing reports: Nephrolithiasis, renal colic, renal pain[Ref]
See also:
AndroGel
AndroGel is used to treat conditions in men that result from a lack of natural testosterone. Learn ...
Xyosted
Xyosted is used to treat men who have low or no testosterone due to certain medical conditions ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Pregnyl
Pregnyl is used for female infertility, hypogonadism, male, ovulation induction, prepubertal ...
Depo-Testosterone
Depo-Testosterone is used for breast cancer, palliative, delayed puberty, male, hypogonadism, male ...
HCG
HCG is used to cause ovulation and to treat infertility in women. Learn about side effects ...
Jatenzo
Jatenzo is used used to treat adult men who have low or no testosterone due to certain medical ...
Gonal-f
Gonal-f is used for follicle stimulation, hypogonadism, male, ovulation induction
References
1. (2001) "Product Information. Androderm (testosterone topical)." SmithKline Beecham
2. (2002) "Product Information. Testopel (testosterone)." Bartor Pharmacal Co, Inc
3. Cerner Multum, Inc. "UK Summary of Product Characteristics."
4. Cerner Multum, Inc. "Australian Product Information."
5. (2014) "Product Information. Depo-Testosterone (testosterone)." Pfizer U.S. Pharmaceuticals Group
6. (2014) "Product Information. Testosterone Enanthate (testosterone)." West Ward Pharmaceutical Corporation
7. (2014) "Product Information. Aveed (testosterone)." Endo Pharmaceuticals Solutions Inc
8. (2015) "Product Information. Testim (testosterone)." A-S Medication Solutions
9. (2015) "Product Information. Fortesta (testosterone)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)
10. (2015) "Product Information. Axiron (testosterone)." Lilly, Eli and Company
11. Traupe H, von Muhlendahl KE, Bramswig J, Happle R (1988) "Acne of the fulminans type following testosterone therapy in three excessively tall boys." Arch Dermatol, 124, p. 414-7
12. Bates GW, Cornwell CE (1991) "Iatrogenic causes of hirsutism." Clin Obstet Gynecol, 34, p. 848-51
13. Fyrand O, Fiskaadal HJ, Trygstad O (1992) "Acne in pubertal boys undergoing treatment with androgens." Acta Derm Venereol, 72, p. 148-9
14. O'Driscoll JB, August PJ (1990) "Exacerbation of psoriasis precipitated by an oestradiol-testosterone implant." Clin Exp Dermatol, 15, p. 68-9
15. Bennett NJ (1998) "A burn-like lesion caused by a testosterone transdermal system." Burns, 24, p. 478-80
16. Buckley DA, Wilkinson SM, Higgins EM (1998) "Contact allergy to a testosterone patch." Contact Dermatitis, 39, p. 91-2
17. Wu FC, Farley TM, Peregoudov A, Waites GM (1996) "Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organizatio Task Force on Methods for the Regulation of Male Fertility." Fertil Steril, 65, p. 626-36
18. DeSanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N (1998) "Clinical experience using the Androderm (R) testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major." J Pediatr Endocrinol Metab, 11, p. 891-900
19. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA (1999) "Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men." J Clin Endocrinol Metab, 84, p. 3469-78
20. Matsumoto AM (1990) "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production." J Clin Endocrinol Metab, 70, p. 282-7
21. Cefalu WT, Pardridge WM, Premachandra BN (1985) "Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia." J Clin Endocrinol Metab, 61, p. 783-6
22. Becker U, Gluud C, Bennett P (1988) "The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men." Liver, 8, p. 219-24
23. Tripathy D, Shah P, Lakshmy R, Reddy KS (1998) "Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathi hypogonadotrophic hypogonadism." Horm Metab Res, 30, p. 642-5
24. Ferrera PC, Putnam DL, Verdile VP (1997) "Anabolic steroid use as the possible precipitant of dilated cardiomyopathy." Cardiology, 88, p. 218-20
25. Zelissen PM, Stricker BH (1988) "Severe priapism as a complication of testosterone substitution therapy." Am J Med, 85, p. 273-4
26. Jackson JA, Waxman J, Spiekerman AM (1989) "Prostatic complications of testosterone replacement therapy." Arch Intern Med, 149, p. 2365-6
27. Parker LU, Bergfeld WF (1991) "Virilization secondary to topical testosterone." Cleve Clin J Med, 58, p. 43-6
28. Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D (1987) "Priapism in Fabry's disease during testosterone treatment." Klin Wochenschr, 65, p. 925
29. Wang C, Leung A, Superlano L, Steiner B, Swerdloff RS (1997) "Oligozoospermia induced by exogenous testosterone is associated with normal functioning residual spermatozoa." Fertil Steril, 68, p. 149-53
30. Anderson FH, Francis RM, Faulkner K (1996) "Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascula risk factors." Bone, 18, p. 171-7
31. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1999) "A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men." J Clin Endocrinol Metab, 84, p. 3642-7
32. Bhasin S, Storer TW, Javanbakht M, et al. (2000) "Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels." JAMA, 283, p. 763-70
33. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ (1994) "Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men." J Clin Endocrinol Metab, 79, p. 561-7
34. Lajarin F, Zaragoza R, Tovar I, Martinezhernandez P (1996) "Evolution of serum lipids in two male bodybuilders using anabolic steroids." Clin Chem, 42, p. 970-2
35. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL (1996) "Testosterone decreases lipoprotein(a) in men." Am J Cardiol, 77, p. 1244
36. Stannard JP, Bucknell AL (1993) "Rupture of the triceps tendon associated with steroid injections." Am J Sports Med, 21, p. 482-5
37. Pollard M (1990) "Tumorigenic effect of testosterone." Lancet, 336, p. 1518
38. Uzych L (1992) "Anabolic-androgenic steroids and psychiatric-related effects: a review." Can J Psychiatry, 37, p. 23-8
39. Falk H, Thomas LB, Popper H, Ishak KG (1979) "Hepatic angiosarcoma associated with androgenic-anabolic steroids." Lancet, 2, p. 1120-3
40. Carrasco D, Prieto M, Pallardo L, Moll JL, Cruz JM, Munoz C, Berenguer J (1985) "Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature." J Hepatol, 1, p. 573-8
41. Nuzzo JL, Manz HJ, Maxted WC (1985) "Peliosis hepatis after long-term androgen therapy." Urology, 25, p. 518-9
42. Yu MW, Chen CJ (1993) "Elevated serum testosterone levels and risk of hepatocellular carcinoma." Cancer Res, 53, p. 790-4
Frequently asked questions
- Is Jatenzo cost covered by insurance?
- Is Xyosted a controlled substance?
- What are the brands of testosterone?
More about FIRST-Testosterone (testosterone)
- Check interactions
- Compare alternatives
- Reviews (1)
- Latest FDA alerts (7)
- Dosage information
- During pregnancy
- Drug class: androgens and anabolic steroids
- Breastfeeding
Patient resources
Other brands
AndroGel, Xyosted, Depo-Testosterone, Jatenzo, ... +13 more
Professional resources
Other brands
AndroGel, Xyosted, Depo-Testosterone, Jatenzo, ... +13 more
Related treatment guides
Further information
FIRST-Testosterone side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.